araag2/HINT huggingface dataset:
Clinical trial NCT02785172 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-118 vehicle lotion, idp-118 vehicle cream, idp-118 lotion, ultravate cream
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA
             (Body Surface Area) of at least 3%, but no more than 12%. The face, scalp, palms,
             soles, axillae, and intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA (Investigators
             Global Assessment) score of 3 or 4. (The face, scalp, palms, soles, axillae, and
             intertriginous areas are to be excluded in this assessment, if psoriasis is present.)

          -  If female and of childbearing potential, must have a negative urine and serum
             pregnancy test at the Screening visit and negative urine pregnancy at Baseline visit
             prior to randomization.

          -  Subject is willing to comply with study instructions and return to the clinic for
             required visits.

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02785185 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-122 vehicle lotion, idp-122 vehicle cream, idp-122 lotion, ultravate cream
SMILES: CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Subject is willing to comply with study instructions and return to the clinic for
             required visits.

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02788006 (phase 2, status: completed)
Conditions: colorectal adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: regorafenib 160 mg
SMILES: CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal cancer with histological proof

          -  Measurable disease according RECIST 1.1

          -  Age ≥ 70 years

          -  ECOG ≤ 1

          -  Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3,
             bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N,
             TP≥ 70%, Creatinine clairance ≥ 30 mL/min

          -  Patient without response to 5FU chemotherapy or anti-vegf treatment or anti EGFR
             treatment (if RAS wild-type), in progression during this treatment or treatment
             stopped because of toxicities

          -  Geriatric Questionnaires answered

          -  Life-expectancy ≥ 3 months

          -  Informed Consent Signed

        Exclusion Criteria:

          -  Not able to swallow tablets (crushed tablets are not allowed)

          -  Previous treatment with regorafenib or other multikinase treatment

          -  Other cancer during the last 5 years, excepted in-situ cervix cancer, skin cancer non
             melanoma and cancer of the bladder curatively treated

          -  Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the
             last 2 weeks previous inclusion

          -  Toxicity > grade 1 not resolved with previous treatment

          -  Major surgery in the 28 days before the inclusion

          -  Non cicatrized injury, ulcer or bone fracture

          -  Congestive Cardiac insufficiency classe >2 (NYHA)

          -  Unstable angor in the last 3 months

          -  Myocardial Infraction in the 6 months before inclusion

          -  HTA not controlled

          -  Pheochromocytome

          -  Arterial or venous thromboembolism in the past 6 months

          -  Infection of grade > 2

          -  VIH infection

          -  B or C hepatitis necessiting a specific treatment

          -  Cirrhosis

          -  Suspicion of brain metastasis or brain metastasis

          -  Haemorraghe ofgrade >3 in the last weeks

          -  Symptomatic Pulmonary fibrosis

          -  Proteinuria > grade 3

          -  Malabsorption

          -  Allergy know to the treatment or to one similar treatment or to one treatment
             component

          -  Systemic anti-cancer drug during the study or the the last 4 weeks

          -  Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor

          -  Social, psychological or medical condition which can interfere with the study
             participation
Clinical trial NCT02794857 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: np001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of clinically possible, clinically probable (with or without laboratory
             support), or clinically definite ALS (using the revised El Escorial Criteria)

          -  Forced vital capacity greater than or equal to 65% of that predicted for age and
             height

          -  Onset of ALS-related weakness less than 3 years prior to first dose of study drug

          -  Plasma high sensitivity C-reactive protein (hs-CRP) concentration of greater than or
             equal to 0.113 mg/dL at pre-screening/screening

          -  Stable dose (greater than 30 days) of riluzole if undergoing treatment with this agent

          -  For females: Not be of childbearing potential or agree to use adequate birth control
             during the study

        Key Exclusion Criteria:

          -  Life expectancy of less than 6 months

          -  Tracheotomy or be using ventilatory assistance, including Bi-level Positive Airway
             Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)

          -  Active pulmonary disease

          -  Gastrostomy

          -  Stem cell therapy

          -  Immune modulator therapy or participation in studies of other agents within 12 weeks
             of pre-screening/screening

          -  Unstable medical condition other than ALS
Clinical trial NCT02804763 (phase 2, status: completed)
Conditions: systemic lupus erythematosus (sle)
ICD codes: L10.4, L93.0, L93.1, L93.2, M32.9, M32.0, M32.11
Drugs: placebo, dapirolizumab pegol (dzp)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus
             International Collaborating Clinics (SLICC) classification criteria

          -  Moderate to severe SLE disease activity

          -  Evidence for at least 1 of the following SLE markers:

               -  Anti-dsDNA antibodies confirmed by central laboratory or

               -  Low complement confirmed by central laboratory or

               -  Antinuclear antibody (ANA) titer of >= 1:80 in combination with at least 1 of the
                  following: Historical positivity for anti-dsDNA or Positivity for extractable
                  nuclear antigen (anti-ENA) confirmed by central laboratory

          -  The subject is receiving stable SLE standard-of-care medication

        Exclusion Criteria:

          -  Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE

          -  Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the
             opinion of the Investigator, would prevent the subject from completing protocol
             required procedures and assessments.

          -  New or worsening Class III or IV lupus nephritis

          -  Chronic kidney failure stage 3b

          -  Evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell
             deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or
             during the study

          -  Clinically significant active or latent infection (eg. chronic viral hepatitis B or C)

          -  Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent
             TB (LTB) infection

          -  Live/live attenuated vaccines within 6 weeks prior to the first study drug infusion
             (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the
             final dose of study drug

          -  History of thromboembolic events within 12 months of screening

          -  Subject has used protocol defined prohibited medications
Clinical trial NCT02805439 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: s47445 15mg, s47445 50mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients

          -  Fulfilling DSM-5 criteria for Major Depressive Disorder confirmed by the brief
             structured interview M.I.N.I. (single or recurrent episode, current episode ≤ 12
             months, current depressive episode of moderate or severe intensity, with or without
             anxious distress, with or without melancholic features, without mixed features or
             atypical features, without seasonal pattern, without psychotic features, without
             catatonic features, without peripartum onset for the current episode)

          -  Patients treated for the current depressive episode with an antidepressant treatment
             with SSRI (fluoxetine, citalopram, paroxetine, escitalopram or sertraline) given in
             monotherapy at recommended dose for at least 6 weeks and no more than 4 months and
             with a stable dosage for at least 3 weeks

          -  HAM-D total score ≥ 20

          -  Clinical Global Impression Severity of illness (item 1): 6 ≥ CGI-S ≥ 4

          -  Antidepressant Treatment Response Questionnaire (ATQR) < 50% for the current SSRI

          -  Absence of any abnormalities likely to interfere with the conduct of the study (ECG,
             vital signs, laboratory tests, medical history)

        Exclusion Criteria:

          -  Depressive episode of mild intensity according to DSM-5 criteria

          -  All types of depressive episodes other than those occurring in a Major Depressive
             Disorder (Persistent Depressive Disorder (Dysthymia) according to DSM-5 criteria,
             including persistent depressive disorder with intermittent or persistent major
             depressive episode according to DSM-5, Premenstrual Dysphoric Disorder, Substance
             Induced Depressive Disorder, Depressive Disorder due to another Medical Condition,
             Other Specified or Unspecified Depressive Disorder, Bipolar Disorder I or II,
             depressed episode, Schizoaffective Disorder (Depressive or Bipolar type))

          -  Depression onset within 12 months after a stroke

          -  Suicidal risk defined as a score > 3 on the item 3 of the HAM-D scale or in the
             investigator's opinion

          -  Lactose intolerance

          -  Patients with hereditary problems of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption

          -  Resistant depression for the current episode (patients who have not responded to 1
             previous antidepressant treatment before the SSRI taken at an appropriate dose)

          -  Current panic disorder

          -  Obsessive compulsive disorder

          -  Current post traumatic stress disorder, current acute stress disorder

          -  Current or past psychotic disorder

          -  Any severe personality features
Clinical trial NCT02808390 (phase 2, status: terminated)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: ged-0507-34-levo 80 mg, ged-0507-34-levo 160 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor decision
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 and over at the time of signing the informed consent.

          -  Diagnosis of UC with a duration of at least 3 months prior to the Screening Visit.

          -  MMS ≥ 4 to ≤ 8 (range: 0 - 9) prior to randomization in the study

          -  Subjects are required to have a colonoscopy if one has not been performed within 12
             months prior to the Screening Visit.

          -  Subjects who have relapsed on maintenance therapy with doses of 5-ASA ≤ 2.4 g/day

        Exclusion Criteria:

          -  Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic
             colitis, radiation colitis, or diverticular disease-associated colitis.

          -  UC restricted to the distal 15 cm or less (eg, ulcerative proctitis).

          -  Subjects who have had surgery as a treatment for UC or who, in the opinion of the
             Investigator, are likely to require surgery for UC during the study.

          -  Clinical signs suggestive of fulminant colitis or toxic megacolon.

          -  Evidence of pathogenic enteric infection.

          -  History of colorectal cancer or colorectal dysplasia.

          -  Prior use of any TNF inhibitor (or any biologic agent).

          -  Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, or thalidomide.

          -  Use of budesonide-MMx within the last 8 weeks.

          -  Use of oral and/or IV corticosteroids within 2 weeks of the Screening Visit.

          -  Use of immunosuppressants (azathioprine [AZA], 6-mercaptopurine [6-MP] or methotrexate
             [MTX]) within 8 weeks of the Screening Visit.
Clinical trial NCT02813551 (phase 2, status: completed)
Conditions: preeclampsia
ICD codes: O14.10, O14.12, O14.13, O14.14, O14.90, O14.92, O14.93
Drugs: torsemide, placebo
SMILES: CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postpartum women at ≥ 18 years of age

          -  Antepartum/intrapartum or within 24 hours postpartum diagnosis of either:

          -  Preeclampsia

          -  Preeclampsia with severe features

          -  Preeclampsia superimposed to chronic hypertension

        Exclusion Criteria:

          -  Chronic hypertension without superimposed preeclampsia

          -  Gestational hypertension

          -  Urine output < 30 cc/h at time of randomization

          -  Heart failure or pulmonary edema

          -  Hypersensitivity to Torsemide or sulfonylureas

          -  Hypokalemia (serum potassium < 3 mEq/L)

          -  Preexisting diuretic use within 24 hours prior to randomization
Clinical trial NCT02815397 (phase 2, status: terminated)
Conditions: diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 years of age

          -  Diagnosis of DLBCL as documented by medical records and with histology based on
             criteria established by the World Health Organization

               -  subtyping is required for DLBCL

               -  c-myc+ defined as presence of c-myc breaks by karyotype/FISH and/or IHC ≥ 40%;
                  this includes double hits (with bcl-2 breaks found using cytogenetics/FISH)
                  and/or double expressors (with bcl-2 protein expression ≥ 70% by IHC); increased
                  copy number in itself is not considered positivity for c-myc

          -  No prior therapy for diagnosis of DLBCL with exception of steroids

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2 (Appendix B)

          -  Life expectancy of at least 6 months

          -  No history of medication dependent diabetes mellitus

          -  No evidence of acute or chronic metabolic acidosis (baseline venous lactate ≤ 4)

        Exclusion Criteria

          -  Patient already on any class of anti-diabetic medication including metformin, insulin
             analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies
             or clear need for therapeutic intervention based on fasting blood glucose

          -  Known histological transformation from indolent non-Hodgkin Lymphoma (iNHL) or chronic
             lymphocytic leukemia (CLL) to an aggressive form of non-Hodgkin's lymphoma (NHL) (ie,
             Richter transformation)

          -  Burkitt and/or precursor lymphoblastic leukemia/lymphoma.

          -  Presence of known intermediate- or high-grade myelodysplastic syndrome

          -  History of an active of treated non-lymphoid malignancy within the last 3 years
             excluding basal cell and squamous cell skin cancers

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             start of study drug.

          -  Subjects who have currently active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL
             or stable chronic liver disease per investigator assessment)

          -  Renal insufficiency with creatinine > 1.5 x upper limit of normal (ULN) OR creatinine
             clearance of < 45 ml/min as calculated by the Cockcroft-Gault method

          -  CNS or leptomeningeal involvement of lymphoma

          -  HIV positive

          -  Ongoing inflammatory bowel disease

          -  Ongoing alcohol or drug addiction

          -  Pregnancy or breastfeeding

          -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
             -
Clinical trial NCT02819557 (phase 2, status: completed)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: ataluren
SMILES: OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Males ≥2 to <5 years of age

          -  Body weight ≥12 kg

          -  Diagnosis of DMD

          -  Nonsense mutation in at least 1 allele of the dystrophin gene

        Exclusion Criteria:

          -  Participation in any other drug or device clinical investigation

          -  Ongoing use of prohibited concomitant medications
Clinical trial NCT02820519 (phase 2, status: terminated)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: loxapine
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
Reason stopped: 
    intolerable high amount of adverse events
  
Eligibility criteria:

        Inclusion Criteria:

          -  Primarily chemotherapy-induced neuropathic pain (including mixed pain) for at least 3
             months refractory to at least one analgesic compound

          -  Neuropathic pain >= 4 (11-point numeric pain scale) at screening visit (including
             mixed pain)

          -  Age >= 18 years

          -  Body weight between 50 and 150 kg

          -  Given written informed consent

        Exclusion Criteria:

          -  Participation in other interventional clinical studies (currently or within the last 3
             months)

          -  Parkinson's disease, movement disorders (extrapyramidal signs and symptoms) associated
             with antipsychotics, neuroleptic malignant syndrome, other syndromes associated with
             antipsychotics

          -  Severe hypotension with a syncope in history, glaucoma, urinary retention, epilepsy or
             other seizure disorders in history, severe dementia, dementia-related psychosis in
             history, malignancies with a life expectancy of less than 6 months, breast cancer in
             history, other life-threatening conditions

          -  Corrected QT interval (QTc) > 460 ms (females) or > 450 ms (males)

          -  Known alcohol and/or drug abuse

          -  Concomitant intake of antipsychotics, dopamine agonists (Levodopa, bromocriptine,
             lisuride, pergolide, ropinirole, cabergoline, pramipexole, apomorphine),
             alpha-receptor blocking compounds

          -  Compounds with a strong evidence for a clinically relevant QT interval prolongation or
             torsade de pointes risk increase

          -  Strong inhibitors of CYP1A2, CYP2D6, or CYP3A4

          -  Known CYP2D6 Poor metabolizer status

          -  Pregnancy or lactation period

          -  Missing or insufficient contraception in pre- or perimenopausal women

          -  Close Affiliation with the investigational site